European Commission
Can.Heal has produced a dozen reports that will inform both EU policies and national health strategies for personalized cancer treatment and prevention going forward.
EC Approves Amgen's Blincyto as Consolidation Treatment for Certain Newly Diagnosed Leukemia Cases
The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.
AstraZeneca, Daiichi Sankyo Withdraw EU Application for Dato-DXd in Nonsquamous NSCLC
The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
AbbVie's Elahere Approved in Europe for FRα-Positive Ovarian Cancer
Elahere's companion diagnostic, Roche's Ventana FOLR1 (FOLR1-2.1) RxDx assay, also garnered CE marking.